文献速递白血病淋巴瘤

维奈克拉加入hyper-CVAD、奈拉滨与聚乙二醇门冬酰胺酶方案治疗T细胞急性淋巴细胞白血病/淋巴瘤的2期试验长期随访

Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma.
PubMed 文献 · Leukemia · 2024-09-25

本文报告一项2期试验的长期随访结果,纳入145例未经治疗或仅接受极少治疗的成人T细胞急性淋巴细胞白血病/淋巴瘤(T-ALL/LBL)患者,其中46例(33.8%)加入维奈克拉。维奈克拉组2年无进展生存(PFS)和缓解持续时间(DOR)优于原方案组,2年总生存(OS)似乎更好但未达统计学显著;维奈克拉联合方案可耐受。

要点

  • 维奈克拉组(随访24.4个月)2年PFS为87.9%,原方案组(随访89.4个月)为64.1%,p=0.03。
  • 维奈克拉组2年DOR为93.6%,原方案组为69.2%,p=0.005。
  • 发热性中性粒细胞减少是最常见严重不良事件,见于60%患者。

核心结论

  • 在HyperCVAD-奈拉滨-聚乙二醇门冬酰胺酶方案中加入维奈克拉可耐受,并改善缓解持续时间和无进展生存。

研究设计与样本

  • 2期试验的长期随访;2007年8月至2024年12月共治疗145例成人T-ALL/LBL患者,中位年龄35.4岁,其中46例(33.8%)在维奈克拉组。
  • 纳入标准为未经治疗或仅接受极少治疗的成人T-ALL/LBL患者,且器官功能充足。
  • 本分析主要终点为维奈克拉组2年无进展生存(PFS)和总生存(OS)的改善。

主要发现

  • 中位随访62.4个月时,5年PFS为63.7%,缓解持续时间(DOR)为72.0%,OS为66.2%。
  • 维奈克拉组(中位随访24.4个月)2年PFS为87.9%,原方案组(中位随访89.4个月)为64.1%,p=0.03。
  • 维奈克拉组2年DOR为93.6%,原方案组为69.2%,p=0.005。
  • 维奈克拉组2年OS为87.8%,原方案组为73.9%,p=0.16。
  • 发热性中性粒细胞减少是最常见严重不良事件,见于60%患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Optimal frontline use of active agents in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is prudent to improve outcomes. We report the long-term follow-up of the phase 2 trial of HyperCVAD with nelarabine and pegylated asparaginase (Original cohort). In the latest protocol iteration venetoclax was added to the induction/consolidation regimen (Venetoclax cohort). Eligible patients were adults with untreated T-ALL/LBL or after minimal therapy and with adequate organ function. Primary endpoint of this analysis was improvement in 2-year progression free survival (PFS) and overall survival (OS) with venetoclax. From Aug 2007 to Dec 2024, 145 patients, at a median age of 35.4 years, were treated; 46 (33.8%) were in the venetoclax cohort. At median follow-up (mFU) of 62.4 months, 5-year PFS, duration of response (DOR), and OS were 63.7%, 72.0% and 66.2% respectively. In the venetoclax cohort (mFU 24.4 months) 2-year PFS (87.9% versus 64.1%, p = 0.03) and 2-year DOR (93.6% versus 69.2%, p = 0.005) were superior to the original cohort (mFU 89.4 months) and 2-year OS appeared better (87.8% versus 73.9%, p = 0.16). Febrile neutropenia was the most common serious adverse event, seen in 60% patients. The addition of venetoclax to HyperCVAD-nelarabine-pegylated asparaginase was tolerable and led to improvement in DOR and PFS.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ravandi F, Senapati J, Jain N, et al. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024. PMID: 39322712. doi:10.1038/s41375-024-02414-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。